Clinical Significance of Circulating Tumour Cells in Resectable Lung Cancer Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05619562

Enrollment

166

Registered

2022-11-17

Start date

2009-01-31

Completion date

2015-12-31

Last updated

2022-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Circulating Tumor Cell, Non Small Cell Lung Cancer

Brief summary

To determine whether the presence of circulating/disseminated tumour cells (CTCs/DTCs) in the blood and bone marrow of the resectable lung cancer (NSCLC) patients is a negative prognostic factor, and to find correlations with other clinical/pathological disease characteristics.

Interventions

DIAGNOSTIC_TESTDevice for CTC/DTC detection

The CTCs/DTCs will be detected and counted in peripheral blood, tumour draining blood and bone marrow samples.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Non-small cell lung cancer, non-metastatic

Exclusion criteria

Prior neoadjuvant chemoradiotherapy Prior lung cancer Cancer duplicity

Design outcomes

Primary

Measure	Time frame	Description
CEA, EGFR, LunX, c-met and EpCAM mRNA positive circulating tumour cells in lung cancer patients	30 days	The absolute gene expression of CEA, EGFR, LunX, c-met and EpCAM mRNA positive circulating tumour cells(CTCs) isolated from peripheral blood, tumour draining blood and bone marrow samples of lung cancer patients will be measured using real-time RT-PCR method. The gene expression will be normalized per microgram of total mRNA.

Secondary

Measure	Time frame	Description
Cancer specific survival in CTC positive NSCLC patients	5 years	The cancer specific survival, overall survival and disease free survival will be measured from the time of diagnosis to the time of event. Two groups of patients will be compared: A: Patients with the presence of CTCs in peripheral blood, tumour draining blood and bone marrow before NSCLC surgery as described in primary outcome measure. B: Patients with the absence e of CTCs in peripheral blood, tumour draining blood and bone marrow before NSCLC surgery as described in primary outcome measure.

Countries

Czechia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026